Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC) Escudier, B., Roigas, J., Gillessen, S., Srinivas, S., Pisa, P., Vogelzang, N., Fountzilas, G., Peschel, C., Baum, C. M., De Mulder, P. OXFORD UNIV PRESS. 2006: 144

View details for Web of Science ID 000248078900448